| 货号 | 9904S |
| 描述 | Rapamycin is soluble in DMSO and methanol. For experiments with cultured cells, CST recommends pretreating with 10 nM of this inhibitor for one hour prior to stimulation. |
| 是否危险品 | 是 |
| 供应商 | CST |
| 背景 | Rapamycin is a bacterial macrolide with antifungal and immunosuppressant activities (1). Rapamycin forms a complex with the immunophilin FKBP12 which then inhibits the activity of FRAP/ mTOR (TOR in yeast) (2,3). Rapamycin treatment of cells leads to the dephosphorylation and inactivation of p70 S6 kinase. Rapamycin also leads to the dephosphorylation of 4E-BP1/PHAS1, thereby promoting its binding to and inactivation of eIF4E (4,5). This activity has been shown to be the basis for Rapamycins ability to block protein synthesis and to arrest cell cycle progression in the G1-phase (6,7). However, it has been suggested that Rapamycins inhibition of the G1/S transition may be the consequence of its effect on cyclin D1 mRNA and protein stability (8). |
| 存放说明 | -20C |
| 参考文献 | Dumont, F. J. et al. (1990) J. Immunol. 144, 251-258. Brown, E. J. et al. (1994) Nature 369, 756-758. Kunz, J. et al. (1993) Cell 73, 585-596. Jefferies, H. B. et al. (1997) EMBO J. 15, 3693-3704. Beretta, L. et al. (1996) EMBO J. 15, 658-664. Thomas, G. and Hall, M.N. (1997) Curr. Opin. Cell. Biol. 9, 782-787. Dennis, P. B. et al. (1999) Curr. Opin. Genet. & Develop. 9, 49-54. Hashemolhosseini, S. et al. (1998) J. Biol. Chem. 273, 14424-14429. |
Western blot analysis of extracts from NIH/3T3 cells, untreated or treated with serum in the presence of the indicated concentrations of Rapamycin, using Phospho-p70 S6 Kinase (Thr389) Antibody #9205 (upper), total p70 S6 kinase antibody #9202 (middle) or Phospho-p44/42 MAPK (Thr202/Tyr204) Antibody #9101 (lower). Western 分析NIH/3T3 细胞提取物，在雷帕霉素存在的条件下分为未处理组和血清处理组。所用抗体为Phospho-p70 S6 Kinase (Thr389) Antibody #9205 (上), total p70 S6 kinase antibody #9202 (中) or Phospho-p44/42 MAPK (Thr202/Tyr204) Antibody #9101 (下). |
